I am a scientist and entrepreneur who has driven human therapeutics from idea...

... to Series A

Idea

Scientific literature

As seen in:

​

​

Press

"The potential applications of RCas9 are seemingly boundless."

​

"Such an approach has the potential to be applied to diverse transcript types in multiple cell systems" 

​

Scientific literature

As seen in:

​

​

Press

"Researchers [have used] CRISPR to fix problems in RNA rather than to change DNA, a promising step for a group of diseases, including Huntington’s and amyotrophic lateral sclerosis, that have no cure."

​

​

Proof of concept

Technical strategy

Business strategy

Early-stage operations

Experience

Co-founder and Chief Technology Officer at Locana, Inc.

​

​

​

Awards

STAT Wunderkind: selected during a nationwide search for "the next generation of scientific superstars" 

​

​

​

BIOCOM Catalyst: among 15 awardees to have made unique contributions to the biotech community in Southern California

​

​

​

​

​

Press

"Locana bags $55M for RNA-targeting gene therapies"

​

​

​

"Locana, Fueled With $55M, Looks to Develop Fixes for Faulty RNA"

Series A

Preclinical development

Published preclinical studies

As seen in:

​

Co-first author of a series of preclinical studies that establish the safety and efficacy of RNA-targeting Cas9 in a model of the most common type of adult-onset muscular dystrophy.